Faculty Profiles - MAEDA Yoshinobu

MISC - MAEDA Yoshinobu

Division display 261 - 280 of about 319 ／ All the affair displays >>

Efficacy and Feasibility of IDEA Therapy for Refractory or Relapsed Non-Hodgkin's Lymphoma International journal

Hisakazu Nishimori, Nobuharu Fujii, Yoshinobu Maeda, Ken-Ichi Matsuoka, Katsuto Takenaka, Katsuji Shinagawa, Kazuma Ikeda, Keitaro Matsuo, Mine Harada, Mitsune Tanimoto

ANTICANCER RESEARCH 29 ( 5 ) 1749 - 1754 2009.5

Language：English Publisher：INT INST ANTICANCER RESEARCH

Background: The effects of a novel salvage regimen, IDEA (ifosfamide, cytosine arabinoside, etoposide and dexamethasone), which does not include anthracycline or platinum, in patients with non-Hodgkin's lymphoma (NHL) were examined. Patients and Methods: Thirty-four patients with refractory or relapsed NHL were treated with IDEA. Results: The overall remission and complete remission rates were 67.6% and 35.3%, respectively. The toxicity of IDEA was tolerable. With a median follow-up of 14 months, one-year overall survival (OS) and progression-free survival rates were 75.1% and 43.7%, respectively. Adequate numbers of CD34(+) cells were obtained in 77.8% of the patients assigned to receive autologous peripheral blood stem cell (PBSC) transplantation. High-dose chemotherapy with autologous PBSC transplantation was carried out in 14 patients; their 3-year OS was 75.0%, with a median followup of 38 months. Conclusion: IDEA is an effective second-line chemotherapy regimen for NHL patients and has an excellent PBSC-mobilizing effect.

Web of Science

PubMed

researchmap

The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis

Hisakazu Nishimori, Keitaro Matsuo, Yoshinobu Maeda, Yuichiro Nawa, Kazutaka Sunami, Kazuto Togitani, Hidetaka Takimoto, Yasushi Hiramatsu, Toru Kiguchi, Tomofumi Yano, Hiromichi Yamane, Takayuki Tabayashi, Makoto Takeuchi, Masanori Makita, Nobuo Sezaki, Yoshiko Yamasuji, Haruko Sugiyama, Takahiro Tabuchi, Itaru Kataoka, Nobuharu Fujii, Fumihiko Ishimaru, Katsuji Shinagawa, Kazuma Ikeda, Masamichi Hara, Tadashi Yoshino, Mitsune Tanimoto

INTERNATIONAL JOURNAL OF HEMATOLOGY 89 ( 3 ) 326 - 331 2009.4

Language：English Publisher：SPRINGER TOKYO

We conducted a retrospective analysis to evaluate the impact on clinical outcomes of adding rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment for diffuse large B-cell lymphoma (DLBCL) patients in Japan. A propensity score method was used to compensate for the non-randomized study design. From January 2000 to December 2004, 378 patients who were newly diagnosed with DLBCL at 13 institutes were enrolled: 123 in the rituximab plus CHOP-based chemotherapy (R+) group, and 255 in the CHOP-based chemotherapy only (R-) group. The complete response rate was significantly higher in the R+ group than in the R- group (77.7 vs. 69.4%, P < 0.001). The progression-free survival (PFS) at 2 years was 62.4% in the R+ group and 57.0% in the R- group. The 2-year overall survival (OS) was 76.9% for the R+ group and 70.5% for the R- group. A multivariate analysis revealed that the addition of rituximab was a strong independent prognostic factor for PFS (hazard ratio 0.64, 95% CI 0.43-0.96, P = 0.031). A subgroup analysis revealed that R+ particularly benefited younger patients (hazard ratio 0.25, 95% CI 0.08-0.75, P = 0.013). IPI also showed significant impact for PFS (hazard ratio 1.82, 95% CI 1.55-2.14 for one score increase, P < 0.001) as well as OS (hazard ratio 2.10, 95% CI 1.71-2.57, P < 0.001). In summary, the addition of rituximab to CHOP-based chemotherapy results in better outcomes for Japanese DLBCL patients, particularly younger patients.

DOI： 10.1007/s12185-009-0259-8

Web of Science

PubMed

researchmap

ミネソタレジメンを用いた臍帯血ミニ移植の治療成績:骨髄移植,末梢血幹細胞移植との比較

小林孝一郎, 原嘉孝, 西森久和, 杉山暖子, 久保西四郎, 前田嘉信, 新谷勝美, 品川克至, 池田和真, 谷本光音

日本臨床腫瘍学会学術集会プログラム・抄録集 7th 2009

Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer.

Hosokawa S, Toyooka S, Fujiwara Y, Tokumo M, Soh J, Takigawa N, Hotta K, Yoshino T, Date H, Tanimoto M, Kiura K

Lung Cancer 66 ( 1 ) 107 - 113 2009

Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation

Yasushi Hiramatsu, Yoshinobu Maeda, Nobuharu Fujii, Takashi Saito, Yuichiro Nawa, Masamichi Hara, Tomofumi Yano, Shoji Asakura, Kazutaka Sunami, Takayuki Tabayashi, Akira Miyata, Ken-ichi Matsuoka, Katsuji Shinagawa, Kazuma Ikeda, Keitaro Matsuo, Mitsune Tanimoto

INTERNATIONAL JOURNAL OF HEMATOLOGY 88 ( 5 ) 588 - 595 2008.12

Language：English Publisher：SPRINGER TOKYO

A prospective randomized clinical trial assessed the efficacy and tolerance of micafungin compared with that of standard fluconazole treatment in patients undergoing hematopoietic stem cell transplantation (HSCT). Adult patients (n = 106) were randomly assigned to receive prophylaxis with either micafungin 150 mg (n = 52), or fluconazole 400 mg (n = 52). Success was defined as the absence of suspected, proven, or probable invasive fungal infection (IFI) through the end of therapy and the absence of proven or probable IFI through the end of the 4-week period following treatment. The overall efficacy of micafungin was comparable to that of fluconazole (94 vs. 88%; difference 6.0%; 95% confidence interval, -5.4 to +17.4%; P = 0.295). A total of 2 (4.0%) of 50 patients in the micafungin arm and 6 (12.0%) of 50 patients in the fluconazole arm received empirical antifungal therapy (P = 0.06). Micafungin treatment did not result in increasing adverse effects and had a safe profile as fluconazole in neutropenic patients. This randomized trial indicates that the efficacy and tolerance of micafungin 150 mg was comparable to that of fluconazole 400 mg, suggesting that micafungin at 150 mg daily represents a valuable new treatment option for antifungal prophylaxis in HSCT recipients.

DOI： 10.1007/s12185-008-0196-y

Web of Science

PubMed

researchmap

Cyclosporine, but Not mTOR Inhibitors, Hampers the Reconstitution of Bone Marrow-Derived Tregs in Long-Term Complete Donor chimeras

Haruko Sugiyama, Yoshinobu Maeda, Hisakazu Nishimori, Koichiro Kobayashi, Miyuki Nishie-Kataoka, Takanori Teshima, Mitsune Tanimoto

BLOOD 112 ( 11 ) 812 - 813 2008.11

Unrelated Cord Blood Transplantation after Nonmyeloablative Conditioning: Single Institutional Retrospective Comparison with Bone Marrow or Peripheral Blood Stem-Cell Transplants

Kolchiro Kobayashi, Yoshinobu Maeda, Hisakazu Nishimori, Haruko Sugiyama, Kazutoshi Aoyama, Tomoko Kikuchi, Noriko Namba, Shiro Kubonishi, Masami Niiya, Katsuji Shinagawa, Kazuma Ikeda, Mitsune Tanimoto

BLOOD 112 ( 11 ) 687 - 687 2008.11

Identification of CD123(+) myeloid dendritic cells as an early-stage immature subset with strong tumoristatic potential

Jun Shi, Kazuma Ikeda, Yosinobu Maeda, Katsuji Shinagawa, Aiji Ohtsuka, Hajime Yamamura, Mitsune Tanimoto

CANCER LETTERS 270 ( 1 ) 19 - 29 2008.10

Language：English Publisher：ELSEVIER IRELAND LTD

CD123 has been identified as a specific surface marker for plasmacytoid dendritic cells (PDCs). However, CD123 has recently been shown to be expressed on freshly isolated or in vitro generated myeloid dendritic cells (MDCs). In this article, we investigated whether the expression of CD123 on monocyte-derived MDCs was related to their function, especially to tumor-inhibiting potential. MDCs were induced from cord blood CD14(+) monocytes with granulocyte-macro phage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) for 7 days, and then CD123(+) cells were isolated by positive immunomagnetic cell selection. We observed that CD123(+) cells lost monocyte CD14 expression, acquired immature myeloid dendritic cell phenotype and morphology. They exerted more significant endocytosis and less antigen-presenting function than CD123-MDCs which are often referred to as typical MDCs. Meanwhile, CD123(+) MDCs exhibited more significant tumor-inhibiting activity toward hematological tumor cell lines of U937 and Jurkat even at a low effector:target ratio. CD123(+) MDCs expressed higher level of cytoplasmic TNF-alpha-related apoptosis-inducing ligand (TRAIL), but no detectable surface TRAIL and very little soluble TRAIL. Pretreatment with recombinant human TRAIL receptor 2:Fc fusion protein significantly reduced the tumor-inhibiting effect of CD123(+) MDCs, but not of CD123(-) MDCs. Overall, our data demonstrated that CD123(+) MDCs were an early-stage immature DC subset, with a significant tumor-inhibiting activity partially via involvement of enhanced cytoplasmic TRAIL. (c) 2008 Elsevier Ireland Ltd. All rights reserved.

DOI： 10.1016/j.canlet.2008.04.048

Web of Science

researchmap

治療抵抗性進行期低悪性度リンパ腫に対する骨髄非破壊的同種造血幹細胞移植

久保西四郎, 品川克至, 浅田騰, 遠西大輔, 門久幸代, 近藤正太郎, 前田嘉信, 新谷勝美, 池田和真, 谷本光音

臨床血液 49 ( 9 ) 1164 - 1164 2008.9

Combined Th2 cytokine deficiency in donor T cells aggravates experimental acute graft-vs-host disease International journal

Isao Tawara, Yoshinobu Maeda, Yaping Sun, Kathleen P. Lowler, Chen Liu, Tonionii Toubai, Andrew N. J. McKenzie, Pavan Reddy

EXPERIMENTAL HEMATOLOGY 36 ( 8 ) 988 - 996 2008.8

Language：English Publisher：ELSEVIER SCIENCE INC

The rote of T helper (Th) 1 and Th2 polarization in acute graft-vs-host-disease (GVHD) is unclear. We investigated the role of Th2 cytokine secretion by utilizing donor T cells that cannot make interleukin (IL)-4, IL-5, IL-9, and IL-13 from quadruple cytokine-deficient (Quad-KO) animals, in a well-characterized BALB/c - C57BL/6 model of allogeneic bone marrow transplantation. B6 recipients of BALB/c Quad-KO T cells demonstrated greater clinical severity, target organ damage, and mortality from GVHD than recipients of BALB/c wild-type (WT) T cells. When compared with donor T cells that are deficient in signal transducers and activators of transcription 6 signaling or the signature Th2 cytokine, IL-4, Quad-KO T cells demonstrated greater GVHD mortality. Mechanistic studies demonstrated that Quad-KO T cells demonstrated enhanced T-cell proliferation than WT T cells when stimulated with either allogeneic antigen-presenting cells or with nonspecific stimuli, such as anti-CD3 monoclonal antibody. Quad-KO T cells also secreted greater amounts of Th1 cytokines and IL-17 compared to WT T cells. Deficiency of Th2 cytokines, however, did not alter the allospecific cytotoxic responses, the numbers of immunoregulatory CD4(+)CD25(+) Foxp3(+) T cells or their suppressive functions. Our data thus unequivocally demonstrate that deficiency of the four classical Th2 cytokine enhances T-cell proliferative responses and aggravates GVHD. (c) 2008 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.

DOI： 10.1016/j.exphem.2008.02.010

Web of Science

PubMed

researchmap

Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice International journal

Pavan Reddy, Yaping Sun, Tomomi Toubai, Raimon Duran-Struuck, Shawn G. Clouthier, Elizabeth Weisiger, Yoshinobu Maeda, Isao Tawara, Oleg Krijanovski, Erin Gatza, Chen Liu, Chelsea Malter, Paolo Mascagni, Charles A. Dinarello, James L. M. Ferrara

JOURNAL OF CLINICAL INVESTIGATION 118 ( 7 ) 2562 - 2573 2008.7

Language：English Publisher：AMER SOC CLINICAL INVESTIGATION INC

Histone deacetylase (HDAC) inhibitors are antitumor agents that also have antiinflammatory properties. However the mechanisms of their immunomodulatory functions are not known. We investigated the mechanisms of action of 2 HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA) and ITF 2357, on mouse DC responses. Pretreatment of DCs with HDAC inhibitors significantly reduced TLR-induced secretion of proinflammatory cytokines, suppressed the expression of CD40 and CD80, and reduced the in vitro and in vivo allo-stimulatory responses induced by the DCs. In addition, injection of DCs treated ex vivo with HDAC inhibitors reduced experimental graft-versus-host disease (GVHD) in a murine allogeneic BM transplantation model. Exposure of DCs to HDAC inhibitors increased expression of indoleamine 2.3-dioxygenase (IDO), a suppressor of DC function. Blockade of IDO in WT DCs with siRNA and with DCs from IDO-deficient animals caused substantial reversal of HDAC inhibition-induced in vitro suppression of DC-stimulated responses. Direct injection of HDAC inhibitors early after allogeneic BM transplantation to chimeric animals whose BM-derived cells lacked IDO failed to protect from GVHD, demonstrating an in vivo functional role for IDO. Together, these data show that HDAC inhibitors regulate multiple DC functions through the induction of IDO and suggest that they may represent a novel class of agents to treat immune-mediated diseases.

DOI： 10.1172/JCI34712

Web of Science

PubMed

researchmap

同種造血幹細胞移植後再発・生着不全に対する再移植

小林孝一郎, 近藤正太郎, 片岡美由紀, 原嘉孝, 西森久和, 杉山暖子, 菊池智子, 久保西四郎, 前田嘉信, 新谷勝美, 品川克至, 池田和真, 谷本光音

日本臨床腫瘍学会学術集会プログラム・抄録集 6th 2008

Lymphopenia-induced proliferation of donor T cells reduces their capacity for causing acute graft-versus-host disease

Yoshinobu Maeda, Isao Tawara, Takanori Teshima, Chen Liu, Daigo Hashimoto, Ken-ichi Matsuoka, Mitsune Tanimoto, Pavan Reddy

EXPERIMENTAL HEMATOLOGY 35 ( 2 ) 274 - 286 2007.2

Language：English Publisher：ELSEVIER SCIENCE INC

Objective. T cells that undergo lymphopenia-induced proliferation (LIP) are characterized by greater effector and anti-tumor function than naive T cells. But the ability of these T cells in causing graft-versus-host disease (GVHD) is not known.
Methods. We tested the hypothesis that donor T cells that had undergone LIP would cause more severe GVHD than naive T cells by utilizing well-characterized murine experimental models of allogeneic bone marrow transplantation (BMT).
Results. Contrary to our hypothesis, LIP of donor T cells under either noninflammatory or irradiated conditions caused significantly reduced GVHD as determined by survival, clinical, pathologic, and biochemical parameters than naive T cells. Compared to naive donor T cells, LIP T cells demonstrated reduced expansion in vivo and in vitro after allogeneic BMT. The reduction in GVHD mortality and severity was observed across multiple strains after allogeneic BMT. In vivo mechanistic studies by cell depletion demonstrated an increase in the CD44(hi) "memory" phenotype T cells and not the CD4(+)CD25(+) T cell subset to be critical for the reduction in GVHD.
Conclusions. These data demonstrate that LIP of T cells regulates acute GVHD severity in contrast to their ability to cause increased allograft rejection, autoimmunity, or anti-tumor immunity. (c) 2007 International Society for Experimental Hematology. Published by Elsevier Inc.

DOI： 10.1016/j.exphem.2006.10.010

Web of Science

researchmap

Lymphopenia-induced proliferation of donor T cells reduces their capacity for causing acute graft-versus-host disease International journal

Yoshinobu Maeda, Isao Tawara, Takanori Teshima, Chen Liu, Daigo Hashimoto, Ken-ichi Matsuoka, Mitsune Tanimoto, Pavan Reddy

EXPERIMENTAL HEMATOLOGY 35 ( 2 ) 274 - 286 2007.2

Language：English Publisher：ELSEVIER SCIENCE INC

DOI： 10.1016/j.exphem.2006.10.010

Web of Science

PubMed

researchmap

Predominant infiltration of monocytes in chronic graft-versus-host disease

Noriko Namba, Katsuii Shinagawa, Nobuharu Fujii, Yoshinobu Maeda, Fumihiko Ishimaru, Kazurna Ikeda, Toshimitsu Matsui, Mitsune Tanimoto, Yoshio Katayama

TRANSPLANTATION 83 ( 2 ) 220 - 224 2007.1

Language：English Publisher：LIPPINCOTT WILLIAMS & WILKINS

Pathogenesis of chronic graft-versus-host disease (cGVHD) is largely unknown. It is important to determine the responsible cell types and the factors that play roles to recruit these cells into sites of disease. We examined whether monocytes and chemokine fractalkine/receptor CX3CR1 axis might be involved. We found that the absolute number of CX3CR1 + monocytes in the blood was significantly decreased in patients with severe cGVHD. Immunohistochemical staining revealed the extensive infiltration of CD 14 + cells as well as strong expression of fractalkine in the cGVHD skin. The number of infiltrated CD14+ cells on the margin of fractatkine+ epidermis was larger in cGVHD skin compared to that of acute graft-versus-host disease, whereas no difference was observed in CD3 + T cells. These results suggest that CX3CR1+ monocytes may be recruited from the circulation to the fractalkine + epidermis in cGVHD, and highlight these cells and this chemokine/receptor axis as additional targets for cGVHD therapy.

DOI： 10.1097/01.tp.0000245080.71722.87

Web of Science

researchmap

Predominant infiltration of monocytes in chronic graft-versus-host disease International journal

Noriko Namba, Katsuii Shinagawa, Nobuharu Fujii, Yoshinobu Maeda, Fumihiko Ishimaru, Kazurna Ikeda, Toshimitsu Matsui, Mitsune Tanimoto, Yoshio Katayama

TRANSPLANTATION 83 ( 2 ) 220 - 224 2007.1

Language：English Publisher：LIPPINCOTT WILLIAMS & WILKINS

DOI： 10.1097/01.tp.0000245080.71722.87

Web of Science

PubMed

researchmap

MDSを合併した先端巨大症に対するオクトレオチドによる１治療例

三好智子, 大塚文男, 稲垣兼一, 鈴木二郎, 大谷寛之, 後藤順子, 三村由香里, 小倉俊郎, 影山甚郷, 前田嘉信, 槇野博史

日本内分泌学会雑誌 83 79-81:,2007 2007

MDSを合併した先端巨大症に対するオクトレチオドによる1治療例

三好智子, 大塚文男, 稲垣兼一, 鈴木二郎, 大谷寛之, 後藤順子, 三村由香里, 小倉俊郎, 景山甚郷, 前田嘉信, 槇野博史

日本内分泌学会雑誌 83 79 - 81 2007

Evolution of rituximab as "Standard" therapy in patients (pts) with newly diagnosed diffuse large B cell lymphoma (DLBCL) in Japan: An analysis from West-Japan Hematology/Oncology group (West-JHOG) NRL outcomes project.

Yuichiro Nawa, Keitaro Matsuo, Kazuki Sunami, Kazuto Togitani, Hidetaka Takimoto, Hisakazu Nishimori, Yoshinobu Maeda, Yasushi Hiramatsu, Toru Kiguchi, Tomofumi Yano, Hiromichi Yamane, Takayuki Tabayashi, Makoto Takeuchi, Masanori Makita, Nobuo Sezaki, Kazuma Ikeda, Fumihiko Ishimaru, Katsuji Shinagawa, Masamichi Ham, Mitsune Tanimoto

BLOOD 108 ( 11 ) 257B - 257B 2006.11

Chronic lymphoproliferative disorder with regulatory T-cell phenotype International journal

Tomoko Kikuchi, Yoshio Katayama, Shiro Kubonishi, Toshiyuki Watanabe, Yukari Watanabe, Ken-ichi Matsuoka, Yoshinobu Maeda, Noriko Namba, Taro Masunari, Ryusuke Nasu, Kazuma Ikeda, Mitsune Tanimoto

AMERICAN JOURNAL OF HEMATOLOGY 81 ( 9 ) 713 - 716 2006.9

Language：English Publisher：WILEY-LISS

We report a case of T-cell chronic lymphoproliferative disorder (CLPD) that shows neither features of T-cell prolymphocytic leukemia nor disease progression for more than 34 months. Flow cytometric analyses of the lymphocytes revealed high expression of CD4 and CD25. Up-regulation of Foxp3, a master regulatory gene for developmental differentiation of regulatory T cells (Treg), was confirmed at mRNA and protein levels. To our knowledge, this is the first case of extremely indolent CLPD with Treg phenotype.

DOI： 10.1002/ajh.20688

Web of Science

PubMed

researchmap

　 PREV - NEXT 　

< MAEDA Yoshinobu >

MISC - MAEDA Yoshinobu